151 related articles for article (PubMed ID: 2221983)
1. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon.
Mozzanica N; Cattaneo A; Boneschi V; Brambilla L; Melotti E; Finzi AF
Arch Dermatol Res; 1990; 282(5):311-7. PubMed ID: 2221983
[TBL] [Abstract][Full Text] [Related]
2. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression.
Buechner SA
J Am Acad Dermatol; 1991 May; 24(5 Pt 1):731-4. PubMed ID: 1869644
[TBL] [Abstract][Full Text] [Related]
3. Treatment of basal cell carcinoma with intralesional interferon.
Greenway HT; Cornell RC; Tanner DJ; Peets E; Bordin GM; Nagi C
J Am Acad Dermatol; 1986 Sep; 15(3):437-43. PubMed ID: 3760271
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping.
Sullivan TP; Dearaujo T; Vincek V; Berman B
Dermatol Surg; 2003 Dec; 29(12):1181-6. PubMed ID: 14725659
[TBL] [Abstract][Full Text] [Related]
5. Intralesional interferon in basal cell carcinoma: how does it work?
Buechner S; Wernli M; Bachmann F; Harr T; Erb P
Recent Results Cancer Res; 2002; 160():246-50. PubMed ID: 12079220
[TBL] [Abstract][Full Text] [Related]
6. Intralesional alfa-2a interferon therapy for basal cell carcinoma.
Doğan B; Harmanyeri Y; Baloğlu H; Oztek I
Cancer Lett; 1995 May; 91(2):215-9. PubMed ID: 7767912
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the mononuclear infiltrate in basal cell carcinoma: a predominantly T cell-mediated immune response with minor participation of Leu-7+ (natural killer) cells and Leu-14+ (B) cells.
Habets JM; Tank B; Vuzevski VD; van Reede EC; Stolz E; van Joost T
J Invest Dermatol; 1988 Mar; 90(3):289-92. PubMed ID: 3257999
[TBL] [Abstract][Full Text] [Related]
8. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.
Stenquist B; Wennberg AM; Gisslén H; Larkö O
J Am Acad Dermatol; 1992 Jul; 27(1):65-9. PubMed ID: 1619079
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma.
Alpsoy E; Yilmaz E; Başaran E; Yazar S
J Dermatol; 1996 Jun; 23(6):394-6. PubMed ID: 8708151
[TBL] [Abstract][Full Text] [Related]
10. In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
De Giorgi V; Salvini C; Chiarugi A; Paglierani M; Maio V; Nicoletti P; Santucci M; Carli P; Massi D
Int J Dermatol; 2009 Mar; 48(3):312-21. PubMed ID: 19261026
[TBL] [Abstract][Full Text] [Related]
11. Intralesional interferon therapy for basal cell carcinoma.
Cornell RC; Greenway HT; Tucker SB; Edwards L; Ashworth S; Vance JC; Tanner DJ; Taylor EL; Smiles KA; Peets EA
J Am Acad Dermatol; 1990 Oct; 23(4 Pt 1):694-700. PubMed ID: 2229497
[TBL] [Abstract][Full Text] [Related]
12. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
13. Treatment of basal cell carcinoma with intralesional interferon.
Georgouras K
Australas J Dermatol; 1994; 35(1):47. PubMed ID: 7864996
[No Abstract] [Full Text] [Related]
14. Intralesional interferon-alpha 2b treatment of basal cell carcinoma.
Thestrup-Pedersen K; Jacobsen IE; Frentz G
Acta Derm Venereol; 1990; 70(6):512-4. PubMed ID: 1981427
[TBL] [Abstract][Full Text] [Related]
15. Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review.
McDonald RR; Georgouras K
Australas J Dermatol; 1992; 33(2):81-6. PubMed ID: 1294057
[TBL] [Abstract][Full Text] [Related]
16. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited.
Kim KH; Yavel RM; Gross VL; Brody N
Dermatol Surg; 2004 Jan; 30(1):116-20. PubMed ID: 14692941
[TBL] [Abstract][Full Text] [Related]
17. An absence of human leukocyte antigen-DR and a decreased expression of beta 2-microglobulin on tumor cells of basal cell carcinoma: no influence on the peritumoral immune infiltrate.
Habets JM; Tank B; Vuzevski VD; Stolz E; van Joost T
J Am Acad Dermatol; 1989 Jan; 20(1):47-52. PubMed ID: 2521495
[TBL] [Abstract][Full Text] [Related]
18. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas.
Edwards L; Tucker SB; Perednia D; Smiles KA; Taylor EL; Tanner DJ; Peets E
Arch Dermatol; 1990 Aug; 126(8):1029-32. PubMed ID: 2383027
[TBL] [Abstract][Full Text] [Related]
19. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b.
Fernández-Vozmediano JM; Armario-Hita JC
J Drugs Dermatol; 2010 Apr; 9(4):381-4. PubMed ID: 20514797
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.
Chimenti S; Peris K; Di Cristofaro S; Fargnoli MC; Torlone G
Dermatology; 1995; 190(3):214-7. PubMed ID: 7599384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
